The Association of PTEN Hypermethylation and Breast Cancer: a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Sep 28

PMID 27672335

Citations 18

Authors

Shanshan Luo

Jiansi Chen

Xianwei Mo

Affiliations

Soon will be listed here.

Abstract

Objective: Phosphatase and tensin homolog (PTEN) deleted on chromosome 10, as a tumor suppressor gene, is crucial for the development of both familial and sporadic breast cancer (BC). The aim of this study was to perform a meta-analysis to evaluate the clinicopathological significance of PTEN promoter hypermethylation in BC.

Methods: A comprehensive literature search was made in PubMed, Embase, Google Scholar, Chinese database (China National Knowledge Infrastructure [CNKI]), and Web of Science. The analysis of pooled data was performed with Review Manager 5.2. The fixed-effects or random-effects models were used to evaluate odds ratios (ORs) and 95% confidence intervals (CIs).

Results: The meta-analysis included eight studies and a total of 923 patients. The frequency of PTEN promoter hypermethylation was significantly increased in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) compared to normal breast tissues (OR =22.53, P=0.0002 and OR =22.86, P<0.00001, respectively). However, the frequency of PTEN promoter hypermethylation was similar between IDC and DCIS. Additionally, PTEN methylation was not significantly correlated to estrogen receptor (ER) or human epidermal growth factor type 2 (HER-2) status in patients with BC.

Conclusion: PTEN promoter hypermethylation is significantly associated with the risk of DCIS and IDC, suggesting PTEN promoter hypermethylation is a valuable biomarker for diagnosis of BC.

Citing Articles

Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues.

Wiltshire E, de Moura M, Pineyro D, Joshi R Hum Genomics. 2024; 18(1):24.

PMID: 38475971 PMC: 10935810. DOI: 10.1186/s40246-024-00592-x.

, , microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics.

Travis G, McGowan E, Simpson A, Marsh D, Nassif N Cancers (Basel). 2023; 15(20).

PMID: 37894321 PMC: 10605164. DOI: 10.3390/cancers15204954.

CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Akram F, Ul Haq I, Sahreen S, Nasir N, Naseem W, Imitaz M Technol Cancer Res Treat. 2022; 21:15330338221132078.

PMID: 36254536 PMC: 9580090. DOI: 10.1177/15330338221132078.

CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope.

Karn V, Sandhya S, Hsu W, Parashar D, Singh H, Jha N Cancer Cell Int. 2022; 22(1):234.

PMID: 35879772 PMC: 9316746. DOI: 10.1186/s12935-022-02654-3.

Global DNA Methylation Profiles in Peripheral Blood of WTC-Exposed Community Members with Breast Cancer.

Tuminello S, Zhang Y, Yang L, Durmus N, Snuderl M, Heguy A Int J Environ Res Public Health. 2022; 19(9).

PMID: 35564499 PMC: 9105091. DOI: 10.3390/ijerph19095104.

References

Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P . Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. Hum Mol Genet. 2010; 19(15):2936-46. DOI: 10.1093/hmg/ddq199. View

Pan Q, Li W, Dong H, Chen Y, Yin L, Liu W . PTEN hypermethylation profiles of Chinese Kazakh patients with esophageal squamous cell carcinoma. Dis Esophagus. 2013; 27(4):396-402. DOI: 10.1111/dote.12106. View

Song M, Salmena L, Pandolfi P . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5):283-96. DOI: 10.1038/nrm3330. View

Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S . Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology. 2005; 68(4-6):398-404. DOI: 10.1159/000086981. View

Sakai A, Thieblemont C, Wellmann A, Jaffe E, Raffeld M . PTEN gene alterations in lymphoid neoplasms. Blood. 1998; 92(9):3410-5. View

Atalay C . Epigenetics in breast cancer. Exp Oncol. 2014; 35(4):246-9. View

Marsit C, Zheng S, Aldape K, Hinds P, Nelson H, Wiencke J . PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005; 36(7):768-76. DOI: 10.1016/j.humpath.2005.05.006. View

Dean S, Perks C, Holly J, Bhoo-Pathy N, Looi L, Mohammed N . Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol. 2014; 141(3):323-33. DOI: 10.1309/AJCPR11DEAYPTUSL. View

Tserga A, Michalopoulos N, Levidou G, Korkolopoulou P, Zografos G, Patsouris E . Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep. 2011; 27(5):1630-8. DOI: 10.3892/or.2011.1576. View

10.

Perren A, Weng L, Boag A, Ziebold U, Thakore K, Dahia P . Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999; 155(4):1253-60. PMC: 1867038. DOI: 10.1016/S0002-9440(10)65227-3. View

11.

Li J, Gong P, Lyu X, Yao K, Li X, Peng H . Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker. Oncol Rep. 2014; 31(5):2206-12. DOI: 10.3892/or.2014.3061. View

12.

Li L, Ross A . Why is PTEN an important tumor suppressor?. J Cell Biochem. 2007; 102(6):1368-74. DOI: 10.1002/jcb.21593. View

13.

Yari K, Payandeh M, Rahimi Z . Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran. Tumour Biol. 2015; 37(6):8145-52. DOI: 10.1007/s13277-015-4731-1. View

14.

Rasheed B, Stenzel T, McLendon R, Parsons R, Friedman A, Friedman H . PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997; 57(19):4187-90. View

15.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

16.

Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y . Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer. Biomed Rep. 2014; 2(5):653-658. PMC: 4106585. DOI: 10.3892/br.2014.298. View

17.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

18.

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

19.

Millis S, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S . Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications. Clin Breast Cancer. 2015; 15(6):473-481.e3. DOI: 10.1016/j.clbc.2015.04.008. View

20.

Kang Y, Lee H, Kim W . Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002; 82(3):285-91. DOI: 10.1038/labinvest.3780422. View